Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etelcalcetide - Amgen

Next Previous
Drug Profile

Etelcalcetide - Amgen

Alternative Names: AMG-416; Etelcalcetide hydrochloride; KAI-4169; KAI-4169-HCl; ONO-5163; Parsabiv; Telcalcetide; Velcalcetide; Velcalcetide hydrochloride

Latest Information Update: 18 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KAI Pharmaceuticals
  • Developer Amgen; Ono Pharmaceutical
  • Class Disulfides; Peptides
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism

Most Recent Events

  • 18 Dec 2024 Etelcalcetide is still in phase III trial for Secondary hyperparathyroidism (In adolescents, In children) in Hungary, Greece, Portugal and US (NCT03969329)( EudraCT2018-004608-21)
  • 13 Dec 2024 Etelcalcetide is still in phase III trial for Secondary hyperparathyroidism (In adolescents, In children) in France, Czech Republic, UK, Italy, Lithuania, Belgium, Spain, Germany (NCT03969329)( EudraCT2018-004608-21)
  • 27 Jul 2022 Etelcalcetide is still in phase III trial for Secondary hyperparathyroidism (In adolescents, In children) in Belgium, Greece, Germany, Czech Republic, Portugal, Poland, Hungary, France, Lithuania, Spain, Italy and the UK (NCT03969329) (EudraCT2018-004608-21)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top